Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Entera Bio Ltd. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 10 | 15 | +5 |
| Shares | 4.06M | 4.26M | +196.8K (+4.8%) |
| Value | $2.44M | $7.11M | +$4.68M (+191.9%) |
New holders (7)
Institutions that held Entera Bio Ltd. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 149,869 | $250.3K | 0.00% |
| Susquehanna International Group, LLP | 51,628 | $86.2K | 0.00% |
| Virtu Financial LLC | 22,040 | $37.0K | 0.00% |
| Citadel Advisors LLC | 12,502 | $20.9K | 0.00% |
| Advisor Group Holdings, Inc. | 1,500 | $2.50K | 0.00% |
| JPMorgan Chase & Co | 2 | $3 | 0.00% |
| Simplex Trading, LLC | 295 | $0 | 0.00% |
Sold out (2)
Institutions that held Entera Bio Ltd. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Two Sigma Securities, LLC | 69,441 | $41.7K |
| Morgan Stanley | 1,000 | $600 |